Clinical Trial Update: Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

This Phase 2 trial updates romidepsin for relapsed or refractory acute myeloid leukemia, covering several AML subtypes defined by cytogenetic abnormalities.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with
• Acute Myeloid Leukemia with 11q23 Abnormalities
• Acute Myeloid Leukemia with Del
• Acute Myeloid Leukemia with Inv
• Acute Promyelocytic Leukemia

Drugs mentioned

• Romidepsin (romidepsin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 2 | Status: COMPLETED